Dataset Information

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour^-1 kg^-1, consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.

SUBMITTER: Jones BE

PROVIDER: S-EPMC8284311 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

Jones Bryan E BE Brown-Augsburger Patricia L PL Corbett Kizzmekia S KS Westendorf Kathryn K Davies Julian J Cujec Thomas P TP Wiethoff Christopher M CM Blackbourne Jamie L JL Heinz Beverly A BA Foster Denisa D Higgs Richard E RE Balasubramaniam Deepa D Wang Lingshu L Zhang Yi Y Yang Eun Sung ES Bidshahri Roza R Kraft Lucas L Hwang Yuri Y Žentelis Stefanie S Jepson Kevin R KR Goya Rodrigo R Smith Maia A MA Collins David W DW Hinshaw Samuel J SJ Tycho Sean A SA Pellacani Davide D Xiang Ping P Muthuraman Krithika K Sobhanifar Solmaz S Piper Marissa H MH Triana Franz J FJ Hendle Jorg J Pustilnik Anna A Adams Andrew C AC Berens Shawn J SJ Baric Ralph S RS Martinez David R DR Cross Robert W RW Geisbert Thomas W TW Borisevich Viktoriya V Abiona Olubukola O Belli Hayley M HM de Vries Maren M Mohamed Adil A Dittmann Meike M Samanovic Marie I MI Mulligan Mark J MJ Goldsmith Jory A JA Hsieh Ching-Lin CL Johnson Nicole V NV Wrapp Daniel D McLellan Jason S JS Barnhart Bryan C BC Graham Barney S BS Mascola John R JR Hansen Carl L CL Falconer Ester E

Science translational medicine 20210405 593

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a pot ...[more]

PMID: 33820835

Similar Datasets

Project description:BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.MethodsIn this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes. The primary outcome was the change from baseline in the viral load at day 11. The results of a preplanned interim analysis as of September 5, 2020, are reported here.ResultsAt the time of the interim analysis, the observed mean decrease from baseline in the log viral load for the entire population was -3.81, for an elimination of more than 99.97% of viral RNA. For patients who received the 2800-mg dose of LY-CoV555, the difference from placebo in the decrease from baseline was -0.53 (95% confidence interval [CI], -0.98 to -0.08; P = 0.02), for a viral load that was lower by a factor of 3.4. Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (-0.20; 95% CI, -0.66 to 0.25; P = 0.38) or the 7000-mg dose (0.09; 95% CI, -0.37 to 0.55; P = 0.70). On days 2 to 6, the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo. The percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group.ConclusionsIn this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).

Dataset Information

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

Publications

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets